Literature DB >> 29949147

MiR-203 over-expression promotes prostate cancer cell apoptosis and reduces ADM resistance.

L-Z Chen1, Z Ding, Y Zhang, S-T He, X-H Wang.   

Abstract

OBJECTIVE: Extra-cellular signal regulated kinase (ERK)/mitogen activated protein kinase (MAPK) signaling pathway is widely involved in cell proliferation, apoptosis, and drug resistance. MAPK kinase 1 (MEK1) is the upstream protein kinase of ERK that can activate ERK/MAPK signaling pathway. microRNA 203 (MiR-203) down-regulation is found to be associated with prostate cancer pathogenesis. Bioinformatics analysis showed the complementary targeted relationship between miR-203 and the 3'-UTR of MEK1 mRNA. This study explored the role of miR-203 in regulating prostate cancer cell proliferation, apoptosis, and ADM resistance through affecting MEK1 expression.
MATERIALS AND METHODS: Dual luciferase assay confirmed the targeted relationship between miR-203 and MEK1. MiR-203, MEK1, p-ERK1/2, and B cell lymphoma 2 (Bcl-2) expressions were compared in normal prostate epithelial cells PrEC, prostate cancer cells PC-3M, and drug resistance cells PC-3M/ADM. PC-3M, PC-3M/ADM cell apoptosis and proliferation were detected by using flow cytometry under ADM treatment at IC50 concentration of PC-3M cells. PC-3M cells were cultured in vitro and divided into four groups, including microRNA-normal control (miR-NC), miR-203 mimic, small interfere NC (si-NC), and si-MEK1.
RESULTS: MiR-203 targeted and inhibited MEK1 expression. MiR-203 levels and cell apoptosis were significantly lower, while MEK1, p-ERK1/2, Bcl-2, and cell proliferation were significantly higher in PC-3M/ADM cells compared to the PC-3M cells. MiR-203 mimic and/or si-MEK1 transfection significantly reduced MEK1, p-ERK1/2, and Bcl-2 levels, attenuated cell proliferation, induced cell apoptosis, and decreased drug resistance.
CONCLUSIONS: MiR-203 elevation suppressed prostate cancer PC-3M cell proliferation, promoted apoptosis, and weakened ADM resistance through targeted inhibiting MEK1 expression to alleviate ERK/MAPK signaling pathway and Bcl-2 expression.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29949147     DOI: 10.26355/eurrev_201806_15253

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  7 in total

1.  MicroRNA-200a suppresses prostate cancer progression through BRD4/AR signaling pathway.

Authors:  Han Guan; Zonghao You; Can Wang; Fang Fang; Rui Peng; Likai Mao; Bin Xu; Ming Chen
Journal:  Cancer Med       Date:  2019-02-19       Impact factor: 4.452

2.  MiR-203 acts as a radiosensitizer of gastric cancer cells by directly targeting ZEB1.

Authors:  Ying Jiang; Shan Jin; Shisheng Tan; Qi Shen; Yingbo Xue
Journal:  Onco Targets Ther       Date:  2019-07-30       Impact factor: 4.147

3.  MALAT1 accelerates the development and progression of renal cell carcinoma by decreasing the expression of miR-203 and promoting the expression of BIRC5.

Authors:  Haimin Zhang; Wei Li; Wenyu Gu; Yang Yan; Xudong Yao; Junhua Zheng
Journal:  Cell Prolif       Date:  2019-06-27       Impact factor: 6.831

4.  7SK Acts as an Anti-tumor Factor in Tongue Squamous Cell Carcinoma.

Authors:  Bowen Zhang; Sainan Min; Qi Guo; Yan Huang; Yuzhu Guo; Xiaolin Liang; Li-Ling Wu; Guang-Yan Yu; Xiangting Wang
Journal:  Front Genet       Date:  2021-04-01       Impact factor: 4.599

Review 5.  Systematic review and meta-analysis of the prognostic significance of microRNAs related to metastatic and EMT process among prostate cancer patients.

Authors:  Martyna Parol; Arkadiusz Gzil; Magdalena Bodnar; Dariusz Grzanka
Journal:  J Transl Med       Date:  2021-01-07       Impact factor: 5.531

Review 6.  Non-coding RNA and cholesteatoma.

Authors:  Ivan Jovanovic; Maja Zivkovic; Snezana Jesic; Aleksandra Stankovic
Journal:  Laryngoscope Investig Otolaryngol       Date:  2022-01-07

7.  The Significance of MicroRNAs Expression in Regulation of Extracellular Matrix and Other Drug Resistant Genes in Drug Resistant Ovarian Cancer Cell Lines.

Authors:  Dominika Kazmierczak; Karol Jopek; Karolina Sterzynska; Barbara Ginter-Matuszewska; Michal Nowicki; Marcin Rucinski; Radoslaw Januchowski
Journal:  Int J Mol Sci       Date:  2020-04-09       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.